Supplementary Table 5.
Characteristics of studies included for meta-analysis
| First author | Year | Country | Study design | AF patients (n) | Male (%) | Mean age | Mean follow-up time (days) | Adverse outcome | Cut-off value | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Roldan et al. (20) | 2012 | UK | Cohort | 930 | 470 (50.5) | 76 | 975 | Stroke/TIA, Heart failure, Cardiovascular events | 3.35 pg/mL | 8 |
| Conway et al. (21) | 2004 | UK | Cohort | 77 | 44 (57.1) | 68 | 2305 | Stroke, death, heart failure | 20 pg/mL | 6 |
| Pinto et al. (22) | 2009 | Italy | Cohort | 373 | 237 (63.5) | 66.08 | 1095 | stroke | 0.89 pg/mL | 9 |
| Hijazi et al. (23) | 2015 | Sweden | Cohort | 14954 | 9630 (67.1) | 70 | 694 | Stroke/embolism, Myocardial infarctions bleeding, death | 2.3 pg/mL | 6 |
| Our study | 2018 | China | Cohort | 217 | 118 (54.4) | 63.41 | 760 | Stroke, death | 55.20 pg/mL | 7 |
NOS - Newcastle-Ottawa scale; AF - atrial fibrillation; IL-6 - interleukin-6; TIA - transient ischemic attack